NASDAQ:NKTR

Nektar Therapeutics Stock News

etoro logo Buy NKTR
*Your capital is at risk
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Goldman Sachs analyst Paul Choi upgraded Nektar Therapeutics to Neutral from Sell with a price target of $20, up from $18.
Nektar upgraded to Neutral from Sell at Goldman Sachs Goldman Sachs NKTR
Nektar Therapeutics (NASDAQ:NKTR) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Monday, BidAskClub reports
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa
Wir sitzen zu Hause, haben Zeit und sehen plötzlich, dass sich vor unserem Fenster ganz viel Natur abspielt. Wir erklären Ihnen, was da gerade passiert.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Mizuho
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE